Logo image of TRDA

ENTRADA THERAPEUTICS INC (TRDA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TRDA - US29384C1080 - Common Stock

10.98 USD
+0.02 (+0.18%)
Last: 12/19/2025, 8:19:00 PM
10.98 USD
0 (0%)
After Hours: 12/19/2025, 8:19:00 PM
Fundamental Rating

3

Taking everything into account, TRDA scores 3 out of 10 in our fundamental rating. TRDA was compared to 531 industry peers in the Biotechnology industry. While TRDA has a great health rating, there are worries on its profitability. TRDA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRDA has reported negative net income.
In the past year TRDA has reported a negative cash flow from operations.
In the past 5 years TRDA reported 4 times negative net income.
In the past 5 years TRDA reported 4 times negative operating cash flow.
TRDA Yearly Net Income VS EBIT VS OCF VS FCFTRDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

TRDA has a better Return On Assets (-25.06%) than 71.24% of its industry peers.
Looking at the Return On Equity, with a value of -30.36%, TRDA is in the better half of the industry, outperforming 76.32% of the companies in the same industry.
Industry RankSector Rank
ROA -25.06%
ROE -30.36%
ROIC N/A
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
TRDA Yearly ROA, ROE, ROICTRDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TRDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRDA Yearly Profit, Operating, Gross MarginsTRDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

8

2. Health

2.1 Basic Checks

TRDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TRDA has more shares outstanding
The number of shares outstanding for TRDA has been increased compared to 5 years ago.
There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRDA Yearly Shares OutstandingTRDA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
TRDA Yearly Total Debt VS Total AssetsTRDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

TRDA has an Altman-Z score of 2.79. This is not the best score and indicates that TRDA is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.79, TRDA is doing good in the industry, outperforming 67.86% of the companies in the same industry.
TRDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.79
ROIC/WACCN/A
WACC8.8%
TRDA Yearly LT Debt VS Equity VS FCFTRDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 14.08 indicates that TRDA has no problem at all paying its short term obligations.
TRDA has a better Current ratio (14.08) than 90.04% of its industry peers.
TRDA has a Quick Ratio of 14.08. This indicates that TRDA is financially healthy and has no problem in meeting its short term obligations.
TRDA's Quick ratio of 14.08 is amongst the best of the industry. TRDA outperforms 90.04% of its industry peers.
Industry RankSector Rank
Current Ratio 14.08
Quick Ratio 14.08
TRDA Yearly Current Assets VS Current LiabilitesTRDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

TRDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -256.60%.
Looking at the last year, TRDA shows a very negative growth in Revenue. The Revenue has decreased by -71.42% in the last year.
EPS 1Y (TTM)-256.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-202.86%
Revenue 1Y (TTM)-71.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.75%

3.2 Future

TRDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.13% yearly.
Based on estimates for the next years, TRDA will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-292.52%
EPS Next 2Y-105.1%
EPS Next 3Y-60.93%
EPS Next 5Y34.13%
Revenue Next Year-82.52%
Revenue Next 2Y-57.53%
Revenue Next 3Y-33.26%
Revenue Next 5Y-14.87%

3.3 Evolution

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2030 2031 50M 100M 150M 200M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TRDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRDA Price Earnings VS Forward Price EarningsTRDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRDA Per share dataTRDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as TRDA's earnings are expected to decrease with -60.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-105.1%
EPS Next 3Y-60.93%

More info and screens

0

5. Dividend

5.1 Amount

TRDA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ENTRADA THERAPEUTICS INC

NASDAQ:TRDA (12/19/2025, 8:19:00 PM)

After market: 10.98 0 (0%)

10.98

+0.02 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners76.48%
Inst Owner Change5.32%
Ins Owners0.73%
Ins Owner Change-8.36%
Market Cap419.66M
Revenue(TTM)61.52M
Net Income(TTM)-103.46M
Analysts83.64
Price Target16.83 (53.28%)
Short Float %2.89%
Short Ratio4.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.43%
Min EPS beat(2)-20.31%
Max EPS beat(2)-10.55%
EPS beat(4)2
Avg EPS beat(4)30.34%
Min EPS beat(4)-20.31%
Max EPS beat(4)104.39%
EPS beat(8)5
Avg EPS beat(8)158.15%
EPS beat(12)7
Avg EPS beat(12)114.61%
EPS beat(16)8
Avg EPS beat(16)87.54%
Revenue beat(2)0
Avg Revenue beat(2)-84.32%
Min Revenue beat(2)-88.45%
Max Revenue beat(2)-80.19%
Revenue beat(4)2
Avg Revenue beat(4)27.24%
Min Revenue beat(4)-88.45%
Max Revenue beat(4)179.44%
Revenue beat(8)6
Avg Revenue beat(8)78.29%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.81%
PT rev (3m)-10.81%
EPS NQ rev (1m)5.78%
EPS NQ rev (3m)8.6%
EPS NY rev (1m)-2.12%
EPS NY rev (3m)-2.12%
Revenue NQ rev (1m)47.36%
Revenue NQ rev (3m)130.08%
Revenue NY rev (1m)-16.93%
Revenue NY rev (3m)-4.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.82
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-2.49
EYN/A
EPS(NY)-4.21
Fwd EYN/A
FCF(TTM)-3.41
FCFYN/A
OCF(TTM)-3.36
OCFYN/A
SpS1.61
BVpS8.91
TBVpS8.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.06%
ROE -30.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.95%
Cap/Sales 3.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.08
Quick Ratio 14.08
Altman-Z 2.79
F-Score2
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)144.47%
Cap/Depr(5y)309.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-256.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-202.86%
EPS Next Y-292.52%
EPS Next 2Y-105.1%
EPS Next 3Y-60.93%
EPS Next 5Y34.13%
Revenue 1Y (TTM)-71.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.75%
Revenue Next Year-82.52%
Revenue Next 2Y-57.53%
Revenue Next 3Y-33.26%
Revenue Next 5Y-14.87%
EBIT growth 1Y-313.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-791.76%
EBIT Next 3Y-147.29%
EBIT Next 5YN/A
FCF growth 1Y-217.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-210.18%
OCF growth 3YN/A
OCF growth 5YN/A

ENTRADA THERAPEUTICS INC / TRDA FAQ

Can you provide the ChartMill fundamental rating for ENTRADA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TRDA.


What is the valuation status of ENTRADA THERAPEUTICS INC (TRDA) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTRADA THERAPEUTICS INC (TRDA). This can be considered as Overvalued.


Can you provide the profitability details for ENTRADA THERAPEUTICS INC?

ENTRADA THERAPEUTICS INC (TRDA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ENTRADA THERAPEUTICS INC?

The Earnings per Share (EPS) of ENTRADA THERAPEUTICS INC (TRDA) is expected to decline by -292.52% in the next year.